or Try an Advanced Search...

    Cord Blood Stocks List

    Symbol Grade Name % Change
    FATE F Fate Therapeutics, Inc. -6.76
    THMO F ThermoGenesis Holdings, Inc. 40.00
    BLFS C BioLife Solutions, Inc. 1.52
    CCEL C Cryo-Cell International, Inc. 5.46
    View As Page of Charts
    Related Industries: Biotechnology Medical Care Facilities Medical Devices Medical Instruments & Supplies
    Related Stock Lists: Biology Stem Cell Life Sciences Adult Stem Cell Biotechnology Blood Childbirth Cryopreservation Umbilical Cord Biopharmaceutical Blood Cells Bone Bone Marrow Cell Biology Chimeric Antigen Receptor Clinic Clinical Applications Clinical Development Drug Discovery FDA

    Related ETFs - A few ETFs which own one or more of the above listed Cord Blood stocks.

    Symbol Grade Name Weight
    WDNA D WisdomTree BioRevolution Fund 1.09
    CNCR F Loncar Cancer Immunotherapy ETF 0.87
    PTH D Invesco DWA Healthcare Momentum ETF 0.66
    PSCH C PowerShares S&P SmallCap Health Care Portfolio 0.49
    QQQS C Invesco NASDAQ Future Gen 200 ETF 0.31
    View all Cord Blood ETFs...
    Compare ETFs
    Compare CNCR to PSCH Compare PSCH to QQQS Compare WDNA to PTH

        Cord Blood Stocks Recent News

        Date Stock Title
        Nov 20 FATE Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options
        Nov 19 FATE Wall Street Breakfast Podcast: Fate Therapeutics Rises On Lupus Drug Data
        Nov 18 FATE Fate Therapeutics Shares Rise After 'Promising' Lupus Treatment Results
        Nov 18 FATE Fate stock rallies 37% on positive Phase 1 data for FT819, FT522
        Nov 18 FATE Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence
        Nov 18 FATE Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence
        Nov 15 FATE Fate Therapeutics, Inc. (NASDAQ:FATE) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
        Nov 15 BLFS BioLife Solutions, Inc. (NASDAQ:BLFS) Just Reported And Analysts Have Been Cutting Their Estimates
        Related Industries: Biotechnology Medical Care Facilities Medical Devices Medical Instruments & Supplies
        Related Stock Lists: Biology Stem Cell Life Sciences Adult Stem Cell Biotechnology Blood Childbirth Cryopreservation Umbilical Cord Biopharmaceutical Blood Cells Bone Bone Marrow Cell Biology Chimeric Antigen Receptor Clinic Clinical Applications Clinical Development Drug Discovery FDA
        Cord Blood

        Cord blood is the blood that remains in the umbilical cord and placenta after a baby is born. It is a rich source of stem cells, which are used to treat a variety of medical conditions. Cord blood can be collected and stored for potential future use in a process known as cord blood banking.

        Browse All Tags